"Global BiTE Antibodies Market, Price, Sales & Clinical Trials Insight 2025" Report Highlights:
- Global BiTE Antibody Market Opportunity Insight (2021-2025)
- Currently Only 1 BiTE Commercially Available In Market: Blinatumomab (Blincyto)
- Blincyto Dosage & Market Sales Analysis ( Yearly, Quarterly & Regional Sales)
- Global BiTE Antibody Clinical Trials Indicators by Phase, Company, Country, Indication & Patient Segment
- Global Bispecific T-Cell Engagers Market Dynamics
The research report, "Global BiTE Antibodies Market , Price, Sales & Clinical Trials Insight 2025" reviews about the wide spread applications of the market and how it has been able to over-come the challenges that were widely distributed in the cancer therapeutics market for long period of time. The research report summarizes about the scientific advancement that has led to the amalgamation of applications of monoclonal antibodies into the bispecific cancer antibodies and making it widely acceptable against different types of cancer indications. It is analyzed that the great ongoing trends, opportunities and desirable achievements linked with the bispecific cancer antibody therapy market is set to deliver all the essential constructive applications in terms of healthcare benefits, thus making the market highly discussed cancer therapy in the current era of pharmaceutical industry.
The unique approach of BITE antibody market, widely known as bispecific cancer antibody market involves the innovative methodology of genetic engineering in order to develop an antibody that is able to target two different epitopes at similar time, making the entire cancer targeting process more accurate when compared with monoclonal therapy. Also, the association of the entire market with strong and robust clinical pipeline and research activities in the past as well as in present is believed to completely revolutionize the entire market opportunities held within bispecific cancer antibody market.
The next generation market opportunities held within the therapy with respect to healthcare benefits and making the therapy as a standard treatment regimen are estimated to cause a substantial rise in the market growth rate when compared with other cancer therapies. The large penetration of the bispecific cancer antibody drugs against different cancer indications is also leading to cause certain changes in the entire cancer market. Some of the parameters that are believed to be responsible for the market to be driven in the next few years are: increasing cases of cancer, arrival of innovative technologies, awareness of the applications of bispecific cancer antibody market and wide range of drugs available for different diseases.
As per "Global BiTE Antibodies Market, Price, Sales & Clinical Trials Insight 2025" report findings, it is observed that the entire market is linked with hundreds of high-performance drugs which have led to a decline in the global cancer mortality rate. The ease in the availability of the drugs and the innovative approach of increasing the target specificity are estimated to cause a radical shift in the overall acceptance of the market which was long ago observed for only some of the prominent cancer therapies such as chemotherapy. The entire market is observed to mature rapidly at global level as hundreds of bio-pharmaceutical companies and research centers are getting involved in the extension of the market by the approval of more potent drugs for commercial use. Some of the already pioneering leaders in the market is believed to be causing tremendous acceleration which is unmatchable and unimaginable for a therapy that has been discovered few decades ago. It is analyzed that the future terms of the market will make the market recognized as a standard and dominating treatment regimen for millions of patients.
Table of Contents
1. Bispecific Antibodies: The Next Generation Antibody Therapeutics
1.1 History of Bispecific Antibodies
1.2 Overview to Bispecific Antibodies
2. Advantages of Bispecific Antibody Over Monoclonal Antibody
3. BiTE (Bispecific T Cell Engager) - New Era in Cancer Immunotherapy
4. Structure & Design of BiTE
4.1 Construction of Single Chain Variable Fragment Antibodies
4.2 Bispecific scFv Antibody Expression & Production
5. BiTE Antibody - Mode of Action
5.1 Redirected Target Cell Lysis by BiTE
5.2 T-Cell Activation by BiTE
5.3 Lytic Synapse Formation by BiTE
6. Blinatumomab (Blincyto): The First Approved BiTE Antibody
6.1 Clinical Trials, Approval & Patenting
6.2 Design & Mechanism of Action
6.3 Adverse Drug Reactions & Management
7. Global BiTE Antibody Clinical Trials Indicators
7.1 By Phase
7.2 By Company
7.3 By Country
7.4 By Indication
7.5 By Patient Segment
8. Global BiTE Clinical Pipeline By Company, Indication & Phase
8.1 Preclinical
8.2 Phase-I
9. Global BiTE Antibody Market Overview
9.1 Current Market Scenario
9.2 Blincyto Reimbursement Policy
10. Blincyto - Dosage & Market Sales Analysis
10.1 Dosage of Blincyto in B-ALL
10.2 Current Market Sales Analysis
11. Clinical Pipeline of Bispecific T-Cell Engagers
12. Bridging T-Cells to Tumors: CAR vs BiTEs
13. BiTE: Ongoing Research & Development
13.1 BiTe Based Immunotherapy Treatment for Relapsed Refractory Multiple Myeloma
13.2 Novel DLL3 Targeted BiTE shows Antitumor Activity in Small Cell Lung Cancer
13.3 Preliminary Efficacy of AMG 160 in Metastatic Castration – Resistant Prostate Cancer
14. Global Bispecific T-Cell Engagers Market Dynamics
14.1 Favorable Market Parameters
14.2 Commercialization Challenges
15. Global BiTE Market Future Prospects
16. Competitive Landscape
16.1 Amgen
16.2 Bayers
16.3 Micromet
16.4 Psioxus Therapeutics
16.5 Y Biologics
List of Figures
Figure 1-1: Evolution of Bispecific Antibodies
Figure 1-2: Bispecific Antibodies Structure
Figure 1-3: Formats of Bispecific Antibodies
Figure 2-1: Advantages of Bispecific Antibody over Monoclonal Antibody
Figure 3-1: Structure of Bispecific T-Cell Engagers
Figure 3-2: General Mechanism of BiTE
Figure 4-1: Construction of scFv Antibodies
Figure 4-2: Antibodies Expression & Production in E. coli
Figure 4-3: Expression & Production of Antibodies in CHO System
Figure 4-4: Various Expression Systems for Antibodies
Figure 5-1: Redirected Target T Cell Lysis
Figure 5-2: Synapse Formation by BiTE
Figure 6-1: Blincyto – FDA Approval Year by Indication
Figure 6-2: History of Clinical Trials
Figure 6-3: Blincyto – Patent Approval & Expires Year
Figure 6-4: Design of Blinatumomab
Figure 6-5: Mechanism of Action of Blinatumomab
Figure 7-1: Global - BiTE Antibody Clinical Trials by Phase, 2020 -2025
Figure 7-2: Global - BiTE Antibody Clinical Trials by Company, 2020 -2025
Figure 7-3: Global - BiTE Antibody Clinical Trials by Country, 2020 -2025
Figure 7-4: Global - BiTE Antibody Clinical Trials by Indication, 2020 -2025
Figure 7-5: Global - BiTE Antibody Clinical Trials by Patient Segment, 2020 -2025
Figure 9-1: Global – BiTE Under Development
Figure 9-2: Global – BiTE Market (US$ Million), 2016-2020
Figure 9-3: US – BiTE Market (US$ Million), 2016-2020
Figure 9-4: Global (Excluding US) – BiTE Market (US$ Million), 2016-2020
Figure 9-5: Global – BiTE Market Growth Rate (CAGR %), 2016-2020
Figure 9-6: Global – BiTE Market Future Estimates (US$ Million), 2021 - 2025
Figure 9-7: Global – Avastin & Herceptin Market (US$ Billion), 2017-2019
Figure 9-8: Blincyto - Total Treatment Cost & Reimbursement
Figure 9-9: Blincyto – In Pocket & Out of Pocket Expenditure
Figure 10-1: Induction & Consolidation Cycles in MRD +ve B-ALL
Figure 10-2: Treatment Interval (weeks) Per Cycle
Figure 10-3: Induction, Consolidation & Continued Therapy Cycles in R/R B-ALL
Figure 10-4: Blincyto - Recommended Dose for R/R B-ALL
Figure 10-5: Global - Blincyto Quarterly Sales by Region (US$ Million), Q1’2019
Figure 10-6: Blincyto – Quarterly Sales by Region (%), Q1'2019
Figure 10-7: Global – Blincyto Quarterly Sales (US$ Million), Q1'2018 & Q1'2019
Figure 10-8: Global - Blincyto Sales by Region (US$ Million) Q2’2019
Figure 10-9: Global – Blincyto Sales (US$ Million), Q2’2018 & Q2’2019
Figure 10-10: Global - Blincyto Sales by Region (US$ Million), Q3’2019
Figure 10-11: Global - Blincyto Sales by Region (%), Q3’2019
Figure 10-12: Global – Blincyto Sales (US$ Million), Q3’2018 & Q3’2019
Figure 10-13: Global – Blincyto Sales by Region (US$ Million), Q4’2019
Figure 10-14: Blincyto –Sales Value by Region (%), Q4’2019
Figure 10-15: Global – Blincyto Sales (US$ Million), Q4’2018 & Q4’2019
Figure 10-16: Global – Blincyto Sales (US$ Million), 2017 – 2020
Figure 10-17: Global - Blincyto Sales by Region (%), Q1’2020
Figure 10-18: Global - Blincyto Sales by Region (%), Q2’2020
Figure 10-19: Global - Blincyto Sales by Region (%), Q3’2020
Figure 10-20: Global - Blincyto Sales by Region (%), Q4’2020
Figure 10-21: Global – Blincyto Sales (US$ Millions), Q1’2020 - Q4’2020
Figure 11-1: BiTE in Clinical Trials
Figure 11-2: Combinational Therapies with Blincyto in Clinical Trials
Figure 11-3: HLE BiTE in Clinical Trials
Figure 12-1: BiTE Antibodies
Figure 12-2: Structure of CAR T-Cell
Figure 12-3: Comparison between Bite & CAR T-Cell
Figure 13-1: AMG420 – Clinical Trial Response of Patients
Figure 13-2: Clinical Trials for RRMM
Figure 13-3: AMG757 – Phase 1 Patient Response
Figure 13-4: AMG757 - Cytokine Release Syndrome in Patients
Figure 14-1: Favorable Parameters
Figure 14-2: Commercialization Challenges
Figure 15-1: Global – Cancer Immunotherapy Market Size (US$ Billion), 2020-2025
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen
- Bayers
- Micromet
- Psioxus Therapeutics
- Y Biologics
